Low-Dose Lenalidomide vs Placebo for Non–Transfusion Dependent Low-Risk Del(5q) Myelodysplastic Syndromes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
Lancet Haematol 2024 Jul 18;[EPub Ahead of Print], M Díez-Campelo, F López-Cadenas, B Xicoy, E Lumbreras, T González, M Del Rey González, J Sánchez-García, R Coll Jordà, B Slama, JÁ Hernández-Rivas, S Thepot, T Bernal, A Guerci-Bresler, J Bargay, ML Amigo, C Preudhomme, L Fenwarth, U Platzbecker, KS Götze, A Arar, S Toribio, C Del Cañizo, JM Hernández-Rivas, P FenauxFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.